Načítá se...
Combating acquired resistance to tyrosine kinase inhibitors in lung cancer
The prospective identification and therapeutic targeting of oncogenic tyrosine kinases with tyrosine kinase inhibitors (TKIs) has revolutionized the treatment of patients with non-small cell lung cancer (NSCLC). TKI therapy frequently induces dramatic clinical responses in molecularly defined cohort...
Uloženo v:
| Vydáno v: | Am Soc Clin Oncol Educ Book |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2015
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4734636/ https://ncbi.nlm.nih.gov/pubmed/25993168 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.14694/EdBook_AM.2015.35.e165 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|